U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000032: Abilities Captured through Interactive Video Evaluation (ACTIVE)-seated
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000032: Abilities Captured through Interactive Video Evaluation (ACTIVE)-seated

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Neuroscience (ON)
Division of Neurology I (DN I)

DDT COA Number
DDT COA #000032

Instrument Name
Abilities Captured through Interactive Video Evaluation (ACTIVE)-seated

Disease/Condition
Dystrophinopathy

Concept of Interest
Functional reaching volume (FRV) intended to encompass upper extremity and trunk movement

Context of Use
Children (>4-12 years) and adolescents (12-17 years) and adults with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD)

COA Type
PerfO

Qualification Stage
Letter of Intent-Accepted

Requestor(s)
The Research Institute at Nationwide Children’s Hospital

Contact(s)
Linda Lowes

Date Accepted into CDER’s COA Qualification Program
May 30, 2013

Submission and Regulatory Correspondence History

Qualification Submission

Date

FDA Submission Decision & Recommendations

Date

   

Transition Letter to 507 Process

9/5/19

Back to Top